SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

The FDA's issuance of a Complete Response Letter (CRL) for Regenxbio's RGX-121 gene therapy for Hunter syndrome is driving intense conversation, with the community expressing significant concerns about the trial design, financial implications, and potential dilution amidst broader scrutiny of gene therapy development.

Kyndryl Holdings, Inc. is a technology services company, which engages in the provision of infrastructure services. It operates through the following segments: United States, Japan, Principal Markets, and Strategic Markets. The Principal Markets segment represents the aggregation of operations in Australia, New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, the United Kingdom, and Ireland. The company was founded on December 4, 2020 and is headquartered in New York, NY.

Kyndryl Holdings Inc

Kyndryl is trending as its stock plunged following the abrupt departures of its CFO and general counsel amid an ongoing accounting review, delayed filings, and a lowered outlook for fiscal 2026. The community is sharply divided between those calling it a "falling knife" and comparing it to past accounting scandals, and dip buyers who believe the sell-off is an "overreaction" given its revenue and stating no material impact to core financials is currently expected.

Fiserv, Inc. engages in the provision of financial services technology. It operates through the Merchant and Financial segments. The Merchant segment offers commerce-enabling products and services including merchant acquiring and digital commerce and mobile payment services, and security and fraud protection, stored-value, and pay-by-bank solutions to companies of all sizes. The Financial segment provides products and services such as processing of customer loan and deposit accounts, digital payments, and card transactions to financial institutions and corporate and public sector clients. The company was founded by Leslie M. Muma and George D. Dalton on July 31, 1984 and is headquartered in Milwaukee, WI.

Fiserv, Inc.

FISV is trending intensely ahead of its earnings, with the community sharply divided between those anticipating a strong rebound fueled by perceived undervaluation, recent institutional accumulation, and new leadership's strategic moves, and those fearing another significant drop due to past disappointments, heavy put option activity, and ongoing fintech sector concerns.

Oscar Health, Inc. is a health insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

Oscar Health is currently trending as investors keenly await congressional decisions on ACA subsidies, which could significantly influence its future growth, alongside an upcoming earnings report. Sentiment among the community is polarized, with many bulls anticipating a rally on policy clarity and improved financials, while bears caution about continued losses and sector-wide pressures.

Silvercorp Metals, Inc. engages in the acquisition, exploration, development, and mining of mineral properties and Environmental, Social and Governance practices. It operates through Mining and Administrative segments. The Mining segment includes Henan Luoning, Guangdong, and others. Its products include Silverbearing lead and Zinc Concentrates.The Administrative segment focuses on Vancouver and Beijing. The company was founded by Rui Feng on October 31, 1991 and is headquartered in Vancouver, Canada.

Silvercorp Metals Inc

Silvercorp Metals Inc.

Silvercorp Metals Inc. is trending following a "blow out" earnings report that smashed estimates with strong financial performance and significant cash flow, sparking community discussions focused on the impressive beat and expectations for further guidance.

Upwork, Inc. is an online marketplace which engages in the provision of businesses to find, hire, and pay freelancers for short-term and longer-term projects. Its marketplace offerings include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The company was founded by Odysseas Tsatalos and Efstratios Karamanlakis in December 2013 and is headquartered in Palo Alto, CA.

Upwork Inc

Upwork is trending following its latest earnings report, which highlighted record Q4 profitability and a revenue beat, but was met with a notable share price decline as forward guidance fell below expectations. The community is keenly debating the role of AI, weighing Upwork's deep integration and its platform's use in OpenAI's new SWE-Lancer benchmark against broader concerns about AI's potential to disrupt the gig economy.

AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases. Its mission is to develop disease-modifying therapeutics that aim to resolve fibrosis and restore organ function, enabling patients with these disorders to live fuller and healthier lives. The company was founded by Paolo Michieli, Manuela Cazzanti, Virginia Morello, Federica Caterina Linty, Michael Potter Saunders, and Hans J. W. de Haard in 2017 and is headquartered in Ghent, Belgium.

AgomAb Therapeutics NV - ADR

AgomAb Therapeutics NV is trending as a new IPO with an extremely low float, fueling intense community discussion about its potential for a short squeeze and rapid price movement, while others anticipate a pullback after its initial run.

ON Semiconductor Corp. engages in the provision of intelligent power and sensing solutions with a primary focus on automotive and industrial markets. It operates through the following segments: Power Solutions Group (PSG), Analog and Mixed-Signal Group (AMG), and Intelligent Sensing Group (ISG). The PSG segment offers discrete, module, and integrated semiconductor products that perform multiple application functions, including power switching, signal conditioning, and circuit protection. The AMG segment designs and develops analog, mixed-signal, power management integrated circuits, sensor interface devices, power conversion, signal chain, and voltage regulation devices. The ISG focuses on the design and development of complementary metal oxide semiconductor image sensors, image signal processors, single photon detectors, including silicon photomultipliers, single photon avalanche diode arrays, and short-wavelength infrared products, as well as actuator drivers for autofocus and image stabilization. The company was founded on July 4, 1999 and is headquartered in Scottsdale, AZ.

ON Semiconductor Corp.

ON Semiconductor is trending with a notable sell-off after reporting mixed earnings and issuing a soft Q1 outlook, leading to strong community debate on whether market reaction is overdone. While some express concern over perceived "stabilization" in automotive and industrial markets, others point to the company's strategic focus on AI data center power and recent partnerships as potential long-term catalysts.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is experiencing significant volatility following its mixed Q4 earnings, which showed an EPS beat but a revenue miss and conservative 2026 guidance prioritizing prudent risk management. While the market is punishing PGY, many in the community view the dramatic sell-off as an extreme overreaction given the company's profitability, strong fundamentals, and historically low valuation compared to peers in the fintech and AI sectors.

Booking Holdings, Inc. engages in the provision of online travel and related solutions. The firm offers services through the following brands: Booking.com, Priceline, Agoda, KAYAK, and OpenTable. It provides accommodation reservations including hotels, hostels, apartments, vacation rentals, and other properties. The company was founded by Jay Scott Walker on July 18, 1997, and is headquartered in Norwalk, CT.

Booking Holdings Inc

Booking Holdings is currently trending amidst analyst downgrades and significant market discussion regarding the disruptive potential of Google's expanding AI-powered travel tools, which some view as a threat to its market moat. While some investors see the recent sharp pullback as a buying opportunity, others are concerned about further downside and its implications for the broader online travel agency sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Zacks Research Downgrades Monte Rosa Therapeutics (NASDAQ:GLUE) to Hold

Zacks Research lowered Monte Rosa Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Wednesday...

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Given Average Recommendation of "Moderate Buy" by Brokerages

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the nine brokerages that are presently covering the firm, MarketBeat...

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Sees Large Drop in Short Interest

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Get Free Report) was the target of a large decrease in short interest in the month of January. As of January 15th, there was short interest totaling...

Monte Rosa Therapeutics (NASDAQ:GLUE) Trading Down 6.9% - What's Next?

Monte Rosa Therapeutics (NASDAQ:GLUE) Trading Down 6.9% - Should You Sell...

51,133 Shares in Monte Rosa Therapeutics, Inc. $GLUE Bought by Campbell & CO Investment Adviser LLC

Campbell & CO Investment Adviser LLC acquired a new stake in shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Free Report) during the 3rd quarter, according to its most recent 13F filing with...

Short Interest in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Rises By 20.7%

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Get Free Report) saw a large growth in short interest during the month of December. As of December 31st, there was short interest totaling 8,454,052...

Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the eight brokerages that are currently covering the firm...

Monte Rosa Therapeutics (NASDAQ:GLUE) CEO Markus Warmuth Sells 5,466 Shares

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Get Free Report) CEO Markus Warmuth sold 5,466 shares of the business's stock in a transaction on Wednesday, January 7th. The shares were sold at an...

<ul class="summary-bullets"><li>The company announced pricing of pre-funded warrants to purchase an additional 1.375 million shares at $23.9999 per warrant.</li><li>Monte Rosa also provided underwriters with a 30-day option to purchase up to 1.875 million additional shares at the public offering price.</li><li>The transaction is expected to close by January 12, 2026.</li></ul>Shares of Monte Rosa Therapeutics (GLUE) remain on the retail radar this week after the company priced a $300 million underwritten public offering at a discount to its last closing price.&nbsp;At the time of writing, <a href="https://stocktwits.com/symbol/GLUE">GLUE stock</a> fell 0.7% in premarket trading on Friday.&nbsp;The offering includes 11.125 million shares of common stock priced at $24.00 per share, a 5.1% discount to Thursday’s close at $25.31. Monte Rosa Therapeutics also announced pricing of pre-funded warrants to purchase an additional 1.375 million shares at $23.9999 per warrant.In addition, Monte Rosa also provided the underwriters with a 30-day option to purchase up to 1.875 million additional shares at the public offering price, net of underwriting discounts and commissions. All shares and pre-funded warrants in the offering are being sold by the company.The transaction is expected to close on or about January 12, 2026, with Jefferies, TD Cowen, and Piper Sandler serving as joint book-running managers for the offering. The $300 million raise represents an upsizing from the $200 million offering announced earlier this week.<h2 class="st-heading-2">Stock On Retail Radar</h2>The stock has been in the limelight lately. On Wednesday, GLUE shares surged more than 50% in premarket, before paring some of the gains after the opening bell. The move followed the <a href="https://stocktwits.com/news-articles/markets/equity/why-did-glue-stock-surge-over-50-in-premarket-today-1/cmxzbnHR42E">release</a> of encouraging interim Phase 1 data for MRT-8102 showing strong anti-inflammatory effects in patients with elevated cardiovascular risk.In the study, C-reactive protein levels fell by 85% after four weeks of treatment, with most participants reaching levels associated with lower cardiovascular risk. The drug also delivered deep and sustained target engagement across multiple dose levels. Based on the results, the company plans to advance MRT-8102 into a Phase 2 study later this year.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Despite the premarket slide, retail sentiment on Stocktwits remained in the ‘extremely bullish’ zone over the past 24 hours, amid ‘extremely high’ message volumes. GLUE was among the top trending tickers at the time of writing.<img src="https://news.stocktwits-cdn.com/GLUE_jpg_c79d022259.webp" alt="GLUE.jpg">One user said that the offer price came in higher than expected.<stembedurl>https://stocktwits.com/JacquelineWilder431/message/641308567</stembedurl>Over the past year, GLUE stock has surged nearly 300%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-aqst-stock-plunge-40-in-pre-market-today/cmU2g5ER4df">Why Did AQST Stock Plunge 40% In Pre-Market Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

GLUE Stock Slips Pre-Market After Pricing $300 Million Public Offer At Discount

The offering includes 11.125 million shares of common stock priced at $24.00 per share, a 5.1% discount to Thursday’s close at $25.31.

Equity

<ul class="summary-bullets"><li>Investors brace for twin triggers in trade today: December jobs data and potential Supreme Court ruling on the legality of tariffs.&nbsp;</li><li>The jobs data is expected to dictate whether the Federal Reserve continues its aggressive pivot or hits the brakes on rate cuts.</li><li>Retail sentiment on Stocktwits showed caution toward SPY, while bullishness around tech-heavy QQQ intensified.</li></ul>U.S. stock futures were signaling a cautious start early Friday, with investors watching for two crucial triggers: December jobs data and a potential U.S. Supreme Court ruling on the legality of President Donald Trump’s tariff authority. This verdict could have wide implications for markets and trade policy. As of 3:30 a.m. ET on Friday, Nasdaq 100 futures, S&amp;P 500 futures, Dow futures and the Russell 2000 futures traded flat.On Stocktwits, however, retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>, an exchange-traded fund that tracks the S&amp;P 500 Index, moved to ‘neutral’ from ‘bullish’. While sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> ETF, which tracks the Nasdaq 100 Index, has flipped back to ‘extremely bullish’ from ‘bullish’ a day ago, amid high message volumes.Trending Stocks To Watch Nvidia (NVDA): TSMC, its key manufacturing partner, reported a roughly 20% rise in revenue. Intel (INTC): Trump said he had a ‘great meeting’ with CEO Lip-Bu Tan yesterday.&nbsp;Chevron (CVX), Exxon Mobil (XOM), and SLB (SLB): Stocks are in focus after reports that senior executives from major oil companies are set to meet President Donald Trump, raising expectations around energy policy and domestic production.Disney (DIS): China’s Vice Premier Ding Xuexiang reportedly met Disney CEO Bob Iger in Beijing, encouraging further investment.&nbsp;Glencore (GNLCY): Reports suggest that Rio Tinto is in early talks with Glencore about a potential tie-up that could create the world’s largest mining company, with a combined valuation of nearly $207 billion.General Motors (GM): The company disclosed $7.1 billion in special charges tied to scaling back EV ambitions and restructuring its China operations.Tilray Brands (TLRY): Posted record fiscal Q2 revenue of $218 million, beating Street estimates.&nbsp;Johnson &amp; Johnson (JNJ):&nbsp;Has&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/j-and-j-cuts-deal-with-trump-s-white-house-to-slash-drug-prices-and-dodge-tariffs/cmU2GbnR45p">secured</a> a tariff exemption in exchange for lower drug prices and two new U.S. manufacturing plants as part of its $55B domestic investment plan.&nbsp;CorMedix Therapeutics (CRMD): The company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/cor-medix-stock-rises-after-hours-ceo-locks-in-chairman-seat-bigger-paycheck-and-rich-severance/cmU2TRJR45s">disclosed</a> an expanded role and revised employment terms for CEO Joseph Todisco, following a sharp selloff earlier in the session tied to cautious guidance.Oscar Health: Shares rose nearly 7% after hours after gaining about 3% in regular trading, as&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/oscar-health-stock-surges-over-after-hours-as-house-backs-obamacare-subsidies/cmUcxWmR45N">investors reacted to a House vote backing</a> ACA subsidy extensions, despite a disclosed insider share sale.Opendoor Technologies (OPEN), Rocket Companies (RKT), Offerpad Solutions (OPAD), UWM Holdings (UWMC): U.S. President Donald Trump&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rkt-stock-rallies-on-trump-pledge-to-keep-mortgage-rates/cmU2R4KR45A">said</a> Thursday that he is working to lower mortgage rates for Americans, following several years of elevated borrowing costs.Monte Rosa Therapeutics (GLUE): Shares are in focus after the biotech priced a $300M public offering at $24 per share.&nbsp;Other noteworthy tickers trending on Stocktwits at the time of writing were&nbsp;Ondas Holdings&nbsp;(<a href="https://stocktwits.com/news-articles/markets/equity/onds-stock-soars-to-5-year-highs-on-israel-defense-tie-ups-rebrand-buzz/cmUcUPnR45V">ONDS</a>),&nbsp;Oscar Health Inc. (<a href="https://stocktwits.com/news-articles/markets/equity/oscar-health-stock-surges-over-after-hours-as-house-backs-obamacare-subsidies/cmUcxWmR45N">OSCR</a>), Security Matters (SMX), Baidu (BIDU), Him &amp; Hers Health (HIMS), among others.&nbsp;&nbsp; Other Catalysts To Watch On the economic front, investors are looking ahead to the release of the December Jobs Report at 8:30 a.m. ET. Economists expect the unemployment rate to tick down to 4.5%. Traders will also be listening closely to FOMC Member Neel Kashkari, who is scheduled to speak at 10:00 a.m. ET.For updates and corrections, email newsroom[at]stocktwits[dot]com

Nasdaq, S&P 500 Futures Pause Ahead Of Jobs Report, Trump Tariff Ruling: Why OPEN, INTC, NVDA, TLRY, CRMD Are On Traders' Radar Today

Early signals show futures flat, SPY sentiment cooling, and tech traders turning bullish.

Monte Rosa Therapeutics, Inc. operates as a biotechnology company, which engages in the developing of precision medicines. The company was founded on November 21, 2019 and is headquartered in Boston, MA.

Monte Rosa Therapeutics Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $HOOD earnings on Tuesday?

GLUE
Monte Rosa Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest GLUE News

GLUEMonte Rosa Therapeutics Inc